Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Keeps "Buy" Rating at HC Wainwright

Key Points

• HC Wainwright reaffirmed its “Buy” rating on Arrowhead Pharmaceuticals and maintained a $120 price target, implying 105.59% upside from the cited $58.37 share price. The analyst consensus remains “Moderate Buy,” with an average target of $98.31.
• Arrowhead’s ARO-MAPT candidate produced reductions in tau of up to 73% in an early-stage study of healthy volunteers, supporting optimism around the company’s CNS pipeline. However, the preliminary results do not yet show benefits for cognition or Alzheimer’s disease progression.
• The company reported quarterly revenue of $75.25 million, up 171% year over year and above estimates, but missed expectations with an adjusted loss of $1.36 per share. Shares have traded between $36.02 and $95.49 over the past year, while insiders recently sold shares.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report)'s stock had its "buy" rating reiterated by research analysts at HC Wainwright in a note issued to investors on Thursday, Benzinga reports. They presently have a $120.00 price target on the biotechnology company's stock. HC Wainwright's price target points to a potential upside of 105.59% from the stock's previous close.

Several other analysts also recently issued reports on the company. Piper Sandler restated an "overweight" rating and set a $126.00 price objective (up from $110.00) on shares of Arrowhead Pharmaceuticals in a report on Thursday, July 23rd. Stifel Nicolaus assumed coverage on Arrowhead Pharmaceuticals in a report on Tuesday, July 14th. They issued a "buy" rating and a $98.00 target price on the stock. Royal Bank Of Canada reiterated an "outperform" rating and issued a $100.00 target price on shares of Arrowhead Pharmaceuticals in a report on Monday, August 31st. Morgan Stanley upped their target price on Arrowhead Pharmaceuticals from $100.00 to $120.00 and gave the company an "overweight" rating in a report on Thursday, July 23rd. Finally, B. Riley Financial upped their target price on Arrowhead Pharmaceuticals from $101.00 to $123.00 and gave the company a "buy" rating in a report on Thursday, July 30th. Ten analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Arrowhead Pharmaceuticals has an average rating of "Moderate Buy" and a consensus target price of $98.31.

Arrowhead Pharmaceuticals Price Performance

Shares of NASDAQ ARWR opened at $58.37 on Thursday. Arrowhead Pharmaceuticals has a twelve month low of $36.02 and a twelve month high of $95.49. The company has a current ratio of 5.90, a quick ratio of 5.90 and a debt-to-equity ratio of 1.77. The company has a market capitalization of $8.22 billion, a price-to-earnings ratio of -25.94 and a beta of 1.29. The firm has a 50-day moving average of $76.71 and a two-hundred day moving average of $75.99.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The biotechnology company reported ($1.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by ($0.13). The company had revenue of $75.25 million for the quarter, compared to analyst estimates of $44.17 million. Arrowhead Pharmaceuticals had a negative return on equity of 60.06% and a negative net margin of 47.79%. Arrowhead Pharmaceuticals's quarterly revenue was up 171.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.26) EPS. As a group, analysts expect that Arrowhead Pharmaceuticals will post -3.62 earnings per share for the current fiscal year.

Insider Transactions at Arrowhead Pharmaceuticals

In related news, Director Adeoye Y. Olukotun sold 2,000 shares of the stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $86.96, for a total value of $173,920.00. Following the transaction, the director owned 31,600 shares in the company, valued at approximately $2,747,936. This represents a 5.95% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Michael S. Perry sold 11,600 shares of the stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $87.30, for a total value of $1,012,680.00. Following the completion of the transaction, the director owned 111,459 shares in the company, valued at $9,730,370.70. This represents a 9.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 3.60% of the stock is owned by corporate insiders.

Institutional Trading of Arrowhead Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the business. Sax Wealth Advisors LLC acquired a new stake in Arrowhead Pharmaceuticals in the third quarter valued at approximately $624,000. GAMMA Investing LLC lifted its stake in Arrowhead Pharmaceuticals by 17.1% in the third quarter. GAMMA Investing LLC now owns 4,542 shares of the biotechnology company's stock valued at $297,000 after acquiring an additional 663 shares during the last quarter. QRG Capital Management Inc. lifted its stake in Arrowhead Pharmaceuticals by 7.1% in the second quarter. QRG Capital Management Inc. now owns 4,810 shares of the biotechnology company's stock valued at $392,000 after acquiring an additional 317 shares during the last quarter. Integrated Wealth Concepts LLC lifted its stake in Arrowhead Pharmaceuticals by 5.2% in the second quarter. Integrated Wealth Concepts LLC now owns 8,297 shares of the biotechnology company's stock valued at $676,000 after acquiring an additional 412 shares during the last quarter. Finally, Squarepoint Ops LLC acquired a new stake in Arrowhead Pharmaceuticals in the second quarter valued at approximately $20,859,000. 62.61% of the stock is currently owned by institutional investors and hedge funds.

More Arrowhead Pharmaceuticals News

Here are the key news stories impacting Arrowhead Pharmaceuticals this week:

• Positive Sentiment: ARO-MAPT produced deep and durable reductions in tau, reaching as much as 73% in healthy volunteers. Arrowhead said the study marks the first successful clinical demonstration of its platform achieving substantial target-gene knockdown in the brain, a potentially important milestone for its central-nervous-system pipeline. Arrowhead ARO-MAPT interim clinical data
• Positive Sentiment: The Alzheimer’s candidate’s ability to cross the blood-brain barrier and reduce tau is driving investor enthusiasm, although the current evidence is limited to an early-stage study in healthy volunteers. Positive ARO-MAPT Phase 1/2a data
• Positive Sentiment: HC Wainwright reaffirmed its “buy” rating and set a $120 price target, implying substantial upside from the provided $58.37 reference price. The target reflects increased optimism around ARO-MAPT and Arrowhead’s broader CNS pipeline.
• Neutral Sentiment: Management discussed ARO-MAPT’s interim findings and the TRiM CNS delivery platform, highlighting potential pipeline expansion into additional neurological diseases. Arrowhead ARO-MAPT and TRiM discussion
• Negative Sentiment: The data remain preliminary and were generated in healthy volunteers, so they do not yet establish that ARO-MAPT improves cognition or slows Alzheimer’s progression. Further clinical testing and confirmation in patients will be necessary.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a biopharmaceutical company focused on developing medicines that silence disease-causing genes. Its research is based primarily on RNA interference (RNAi), a biological process that reduces the production of specific proteins by targeting messenger RNA before it can be used to make those proteins.

The company uses its proprietary Targeted RNAi Molecule (TRiM) platform to design and deliver RNAi therapeutics to selected tissues, including the liver and lungs.